Information
45 Jojeong-daero, Hanam-si, Gyeonggi-do, South Korea
+82 31-793-5491
-
Overview
- Summary
- Attoplex Inc. is a company developing home test systems and diagnostic platforms based on molecular immunoassay and IT technologies. Established in 2019 with the goal of realizing One Health and contributing to Healthcare Democratization. Provision of solutions for accurate, convenient, and affordable diagnosis of viral, bacterial infectious diseases, and genetic diseases. Especially, contribution to improving medical accessibility through its point-of-care testing (POCT) platform, GenHome.Attoplex Inc. is a company developing home test systems and diagnostic platforms based on molecular immunoassay and IT technologies. Established in 2019 with the goal of realizing One Health and contributing to Healthcare Democratization. Provision of solutions for accurate, convenient, and affordable diagnosis of viral, bacterial infectious diseases, and genetic diseases. Especially, contribution to improving medical accessibility through its point-of-care testing (POCT) platform, GenHome.
- Key Products/Technologies
- Key product lines include molecular diagnostic kits and the point-of-care testing (POCT) platform, GenHome.Key product lines include molecular diagnostic kits and the point-of-care testing (POCT) platform, GenHome.
- GenHome is an all-in-one molecular diagnostic platform offering PCR-level accuracy and sensitivity with the speed and convenience of rapid antigen tests.GenHome is an all-in-one molecular diagnostic platform offering PCR-level accuracy and sensitivity with the speed and convenience of rapid antigen tests.
- Automation of the entire process within a single-use cartridge, from sample injection to direct nucleic acid extraction, isothermal amplification (LAMP), and lateral flow assay (LFA) readout.Automation of the entire process within a single-use cartridge, from sample injection to direct nucleic acid extraction, isothermal amplification (LAMP), and lateral flow assay (LFA) readout.
- Rapid diagnostic capability, providing molecular diagnostic results within approximately 30 minutes.Rapid diagnostic capability, providing molecular diagnostic results within approximately 30 minutes.
- Inclusion of room-temperature stable direct extraction buffer and lyophilized reagents in the cartridge, enabling distribution and storage without a cold chain.Inclusion of room-temperature stable direct extraction buffer and lyophilized reagents in the cartridge, enabling distribution and storage without a cold chain.
- GenHome Array is a next-generation POCT device capable of simultaneously and automatically testing up to 8 samples.GenHome Array is a next-generation POCT device capable of simultaneously and automatically testing up to 8 samples.
- Molecular diagnostic kits include Real-time PCR kits for various human diseases such as COVID-19, respiratory infections, sexually transmitted infections, gastrointestinal tract infections, and HPV.Molecular diagnostic kits include Real-time PCR kits for various human diseases such as COVID-19, respiratory infections, sexually transmitted infections, gastrointestinal tract infections, and HPV.
- Possession of over 150 products, including diagnostic kits for animal infectious diseases like Avian Influenza Virus and African Swine Fever Virus, and kits for food poisoning and bioterrorism agents.Possession of over 150 products, including diagnostic kits for animal infectious diseases like Avian Influenza Virus and African Swine Fever Virus, and kits for food poisoning and bioterrorism agents.
- Provision of molecular reagent product lines such as nucleic acid extraction kits, qPCR Master Mix, and DNA Ladder.Provision of molecular reagent product lines such as nucleic acid extraction kits, qPCR Master Mix, and DNA Ladder.
- Actively pursuing the development of AI-based diagnostic reagents for high-risk pathogens through collaboration with KAIST.Actively pursuing the development of AI-based diagnostic reagents for high-risk pathogens through collaboration with KAIST.
- Core Advantages
- Possession of the innovative point-of-care testing (POCT) platform, GenHome, combining PCR-level accuracy with the convenience of rapid antigen tests.Possession of the innovative point-of-care testing (POCT) platform, GenHome, combining PCR-level accuracy with the convenience of rapid antigen tests.
- Technological capability to lead the development and commercialization of AI-based diagnostic reagents for high-risk pathogens through an MOU with KAIST.Technological capability to lead the development and commercialization of AI-based diagnostic reagents for high-risk pathogens through an MOU with KAIST.
- Extensive development of over 150 molecular diagnostic items covering human, animal, and environmental fields, along with customized ODM service provision.Extensive development of over 150 molecular diagnostic items covering human, animal, and environmental fields, along with customized ODM service provision.
- Demonstrated technological prowess and quality competitiveness through CES 2024 and CES 2026 Innovation Awards, and numerous domestic and international certifications including CE-IVDD and ISO13485.Demonstrated technological prowess and quality competitiveness through CES 2024 and CES 2026 Innovation Awards, and numerous domestic and international certifications including CE-IVDD and ISO13485.
- Enhanced efficiency in distribution and storage, and improved medical accessibility, due to room-temperature stable reagent technology eliminating the need for a cold chain.Enhanced efficiency in distribution and storage, and improved medical accessibility, due to room-temperature stable reagent technology eliminating the need for a cold chain.
- Market expandability secured by providing integrated health management solutions for humans, animals, and the environment, based on the One Health vision.Market expandability secured by providing integrated health management solutions for humans, animals, and the environment, based on the One Health vision.
- Target Industrie
- Diagnosis of various human diseases in the molecular diagnostics field, including respiratory infections, sexually transmitted infections, gastrointestinal tract infections, HPV, and COVID-19.Diagnosis of various human diseases in the molecular diagnostics field, including respiratory infections, sexually transmitted infections, gastrointestinal tract infections, HPV, and COVID-19.
- Diagnosis of animal infectious diseases in the veterinary field, such as Avian Influenza Virus, African Swine Fever Virus, Foot-and-mouth disease virus, and wildlife diseases.Diagnosis of animal infectious diseases in the veterinary field, such as Avian Influenza Virus, African Swine Fever Virus, Foot-and-mouth disease virus, and wildlife diseases.
- Detection of food poisoning pathogens and bioterrorism agents in the environmental and food safety sectors.Detection of food poisoning pathogens and bioterrorism agents in the environmental and food safety sectors.
- Utilization of point-of-care testing (POCT) systems in hospitals, screening clinics, animal hospitals, primary healthcare facilities, and home self-testing environments.Utilization of point-of-care testing (POCT) systems in hospitals, screening clinics, animal hospitals, primary healthcare facilities, and home self-testing environments.
- Major Markets
- Japan (GenHome patent application)Japan (GenHome patent application)
- Europe (CE-IVDD certification acquired)Europe (CE-IVDD certification acquired)
- United States (CES Innovation Award recipient)United States (CES Innovation Award recipient)
- Certifications/Patents
- Patent registration for a primer set for loop-mediated isothermal amplification for detecting vaginal lactic acid bacteria and a method for detecting vaginal lactic acid bacteria using the same (Application No.: 10-2024-0194041).Patent registration for a primer set for loop-mediated isothermal amplification for detecting vaginal lactic acid bacteria and a method for detecting vaginal lactic acid bacteria using the same (Application No.: 10-2024-0194041).
- Patent registration for GenHome system-based rapid vaginal microbiome testing technology and completion of Japanese patent application for the personal molecular diagnostic system GenHome.Patent registration for GenHome system-based rapid vaginal microbiome testing technology and completion of Japanese patent application for the personal molecular diagnostic system GenHome.
- Possession of multiple patents based on unique technologies in molecular diagnosis and testing.Possession of multiple patents based on unique technologies in molecular diagnosis and testing.
- Acquisition of CE-IVDD certification for COVID-19 molecular diagnostic kits and 9 other products.Acquisition of CE-IVDD certification for COVID-19 molecular diagnostic kits and 9 other products.
- Holding ISO13485 (Medical Devices Quality Management System), ISO9001 (Quality Management System), and ISO14001 (Environmental Management System) certifications.Holding ISO13485 (Medical Devices Quality Management System), ISO9001 (Quality Management System), and ISO14001 (Environmental Management System) certifications.
- Numerous official certifications including Smart Factory certification, Venture Company certification, establishment of affiliated research center, manufacturing approval for in vitro diagnostic medical devices, and LMO research facility approval.Numerous official certifications including Smart Factory certification, Venture Company certification, establishment of affiliated research center, manufacturing approval for in vitro diagnostic medical devices, and LMO research facility approval.
- Recipient of the CES 2024 Innovation Award (GenHome) and CES 2026 Innovation Award (GenHome Array).Recipient of the CES 2024 Innovation Award (GenHome) and CES 2026 Innovation Award (GenHome Array).
Introduction
Location
45 Jojeong-daero, Hanam-si, Gyeonggi-do, South Korea
클릭하여 위치 살펴보기
